Search

everythinglearnresearchcommunity

for

Search:↓

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.

Nicastrin deficiency may cause skin cell damage and pigmentation disorders in humans, similar to effects seen in fish.

Tofacitinib may help treat hair loss in children with alopecia areata.

Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.

Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.

Ritlecitinib can help about 14,000 people with severe hair loss.

2-Hydroxy-1,4-naphthoquinone is a strong 5α-reductase inhibitor.

MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.

Baricitinib effectively treats certain skin conditions but may have serious side effects.

CENPV, a new partner of CYLD, helps regulate ciliary acetylated tubulin and is overexpressed in certain skin tumors.

Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.

China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.

JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.

A new hair loss treatment using dissolving microneedles was found to speed up hair growth and was more effective than daily use of common hair growth drugs.

Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

JAK inhibitors may help treat alopecia areata by reversing hair loss.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.

The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.